


Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P31167C1PREDECESSOR SERIAL NO.
08/945,365**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*APPLICANT
Bax et al.FILING DATE
HerewithPREDECESSOR GROUP
1614**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>[initials]</i>	AA	4,537,887	8/27/85	Rooke et al.	<i>[initials]</i>	<i>[initials]</i>	
	AB	6,051,255	4/18/00	Conley et al	<i>[initials]</i>	<i>[initials]</i>	
	AC	4,282,202	8/4/81	Dowrick	<i>[initials]</i>	<i>[initials]</i>	
	AD	4,301,149	11/17/81	Crowley	<i>[initials]</i>	<i>[initials]</i>	
	AE	4,441,609	4/10/84	Crowley	<i>[initials]</i>	<i>[initials]</i>	
	AF	4,525,352	6/25/85	Cole et al.	<i>[initials]</i>	<i>[initials]</i>	
	AG	4,673,637	6/16/87	Hyman	<i>[initials]</i>	<i>[initials]</i>	
	AH	5,733,577	3/31/98	Myers et al.	<i>[initials]</i>	<i>[initials]</i>	
	AI	5,962,022	10/5/99	Bolt et al.	<i>[initials]</i>	<i>[initials]</i>	
<i>[initials]</i>	AJ	6,077,536	6/20/00	Merrifield et al.	<i>[initials]</i>	<i>[initials]</i>	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>[initials]</i>	BA	WO 96/04907	1996	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BB	WO 95/28927	1995	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BC	WO 91/15197	1991	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BD	2,005,538	1979	Great Britain	<i>[initials]</i>	<i>[initials]</i>		
	BE	EP 0080862	1982	EPO	<i>[initials]</i>	<i>[initials]</i>		
	BF	WO 93/00898	1/21/93	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BG	0 281 200A ✓	2/26/88	EPO	<i>[initials]</i>	<i>[initials]</i>		
	BH	0 389 177A ✓	3/15/90	EPO	<i>[initials]</i>	<i>[initials]</i>		
	BI	1 004 680A ✓	4/11/00	EPO	<i>[initials]</i>	<i>[initials]</i>		
	BJ	WO 00/03695 ✓	1/27/00	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BK	WO 00/12088 ✓	3/9/00	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BL	WO 92/19227 ✓	11/12/92	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BM	WO 93/00898 ✓	1/21/93	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BN	WO 94/16696 ✓	8/4/94	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BO	WO 94/27557 ✓	12/8/94	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BP	WO 94/27600 ✓	12/8/94	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BQ	WO 95/20946 ✓	8/10/95	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BR	WO 95/25516 ✓	9/28/95	WIPO	<i>[initials]</i>	<i>[initials]</i>		
	BS	WO 95/28148 ✓	10/26/95	WIPO	<i>[initials]</i>	<i>[initials]</i>		
<i>[initials]</i>	BT	WO 95/33487 ✓	12/14/95	WIPO	<i>[initials]</i>	<i>[initials]</i>		
<i>[initials]</i>	BU	WO 96/04908 ✓	2/22/96	WIPO	<i>[initials]</i>	<i>[initials]</i>		

ATTY. DOCKET NO.
P31167C1PREDECESSOR SERIAL NO.
08/945,365**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*APPLICANT
Bax et al.FILING DATE
HerewithPREDECESSOR GROUP
1614

Q	BW	WO 96/07408	3/14/96	WIPO				
	BX	WO 96/34605	11/7/96	WIPO				
	BY	WO 97/09042	3/13/97	WIPO				
	BZ	WO 98/35672	8/20/98	WIPO				
	BAA	WO 98/40054	9/17/98	WIPO				
	BAB	WO 98/42311	10/1/98	WIPO				
Q	BAC	WO 98/07424	2/26/98	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Q	CA	Ruberto et al., J. Int. Med. Res., 17 m(2), pp 168-171 (1989)
	CB	Feldmann et al., Can. Med. Assoc. J., Vol. 142(2), pp 115-118 (1990)
	CC	Jacobson et al., Eur. J. clin. Microbiol. Infect. Dis., 12(5), pp 319-324 (1993)
	CD	Cook et al., "Efficacy of Twice-Daily Amoxycillin/Clavulanate etc.", BJC, 50(3), pp 125-128 (1996)
	CE	Behre et al., "Efficacy of Twice-Daily Dosing of amoxycillin/Clavulanate etc.", Infection, 3, pp 163-166
	CF	Hoberman et al., "Equivalent efficacy and reduced occurrence of diarrhea from a new formulation etc." Journal of Pediatric Infect. Dis., 16, pp 463-470 (1997)
	CG	Hoberman et al., "Efficacy of amoxicillin/clavulanate for acute otitis media: relation to Streptococcus pneumoniae susceptibility", Pediatr. Infect Dis Jr., 1996(15), pp 955-962
	CH	Sakellariou et al., "An evaluation of the interaction and plasticizing efficiency of the polyethylene glycols in ethyl cellulose and hydroxypropyl methylcellulose films using the torsional braid pendulum", Int Journal of Pharm, 1986(31), pgs 55-64
	CI	Lerk et al., "Interaction of lubricants and colloidal silica during mixing with excipients", Pharmaceutica Acta Helvetiae, 1997, 52(3) pgs 33-39
	CJ	Oxhamapet et al., "Characterization of moisture interactions in some aqueous-based tablet film coating formulations", Journal Pharm Pharmacol, 1985(37), pgs 385-390
	CK	Parrott, "Densification of Powders by Concavo-Convex Roller Compactor", Journal of Pharm Sciences, March 1981, Vol 70(3), pgs 288-291
	CL	Saarnivaara et al., "Effect of Storage on the Properties of Acetylsalicylic Acid Tablets Coated with Aqueous Hydroxypropyl Methyl-Cellulose Dispersion", Drug Develop and Ind Pharmacy, 1985, 11(2&3), pgs 481-492
	CM	Tondachi et al., "Tablet Coating in an Aqueous System", Drug Develop and Ind Pharmacy, 1977, 3(3), pgs 227-240
	CN	Aulton et al., "The Mechanical Properties of Hydroxypropylmethylcellulose Films Derived from Aqueous Systems", 1981, 7(6), pgs.649-668
	CO	Heikkinen et al., "Short-term use of amoxicillin-clavulanate during upper respiratory tract infection for prevention of acute otitis media", The Journal of Peds, Feb 1995, 126(2), pgs 313-316
Q	CP	Toh, "Amoxycillin with clavulanic acid", The Australian Nurses Journal, Dec/Jan 1995, Volume 18, No. 6, Abstract

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*APPLICANT
Bax et al.FILING DATE
HerewithPREDECESSOR GROUP
1614

	CQ	McLaren et al., "A comparison of the efficacy and tolerability of Augmentin 625 mg po bd versus Augmentin 375 mg po tds in the treatment of acute bacterial exacerbations of chronic bronchitis", <i>British Journal Clin Research</i> , 1994 (5) pgs 1-10
	CR	Beghi et al., "Efficacy and Tolerability of Azithromycin versus Amoxicillin/Clavulanic Acid in Acute Purulent Exacerbation of Chronic Bronchitis", <i>Journal of Chemotherapy</i> , 1995, 7(2), pgs 146-152
	CS	Fraschini et al., "Pharmacokinetics and Tissue Distribution of Amoxicillin plus Clavulanic Acid after Oral Administration in Man", <i>Journal of Chemotherapy</i> , 1990, 2(3), pgs 171-177
	CT	Todd et al., "Amoxicillin/Clavulanic Acid - An Update of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use", <i>Drugs</i> , 1990, 39(2), pgs 264-307
	CU	van Niekerk, "Pharmacokinetic Study of a Paediatric Formulation of Amoxycillin and Clavulanic Acid in Children", <i>European Journal of Clinical Pharmacology</i> , 1985, 29, pgs 235-239
	CV	Fink et al., "A trial of orally administered Augmentin in the treatment of urinary tract infection and lower respiratory tract infection in a children's hospital", <i>Proc Eur Symp on Augmentin</i> , Scheveningen June 1982, 1983: pgs 325-333
	CW	Jeffries et al., "An Initial Assessment of Augmentin for the Treatment of Paediatric Infections in General Practice", <i>The British Journal of Clinical Practice</i> , 1983, 37, pgs 61-66
	CX	1996 MIMS Annual, Twentieth Edition, May 1995, pgs. 8-476 to 8-477
	CY	Amendola et al., "Pediatric suspension of amoxycillin and clavulanic acid in the treatment of bacterial infections of the upper respiratory tract and ear", <i>Minerva Pediatrica</i> , 1989, vol. 41, no. 2, pgs. 97-103
	CZ	Arguedas et al. "In-vitro activity of cefprozil (BMJ 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid", <i>J. Antimicrob. Chemother.</i> , 1991, 27(3), pgs. 311-18
	CAA	Astruc, "Efficacy and tolerance of a new formulation amoxicillin 100 mg - clavulanic acid 12.5 mg in acute otitis media in infants", <i>Annales De Pediatrie</i> , 1992, vol. 39, no. 2, 142-148
	CAB	Baron et al., "Antimicrobial therapy in acute otitis media", <i>Traitement Antibiotique de L'Otite Moyenne Aigue</i> , <i>Annales de Pediatrie</i> , 1991, 38(8), pp 549-555
	CAC	Barry et al., "Effect of Increased Dosages of Amoxycillin in Treatment of Experimental Middle Ear Otitis Due to Penicillin-Resistant <i>Streptococcus pneumoniae</i> ", <i>Antibacterial Agents and Chemotherapy</i> , August 1993, Vol 37, No. 8, pgs. 1599-1603
	CAD	Berry et al., "Bactericidal and morphological effects of amoxicillin on <i>helicobacter pylori</i> ", <i>Antimicrobial Agents and Chemotherapy</i> , vol 39, pgs 1859-1861
	CAE	Berry et al., "Bacteriological efficacy of three macrolides compared with amoxicillin/clavulanate against <i>S. pneumoniae</i> and <i>H. influenzae</i> ", <i>Antimicrobial Agents and chemotherapy</i> , vol. 42, pgs 3193-3199
	CAF	Berry et al., "Comparative Efficacy of Gemifloxacin in Experimental Models of Pyelonephritis and Wound Infection", <i>Journal of Antimicrobial Chemotherapy</i> , 2000, no 45, supplement S1 pgs 79-85
	CAG	Berry et al., "Comparative in vivo activity of gemifloxacin in a rat model of respiratory infection, <i>J. Antimicrob. Chemother.</i> , vol 45, supplement S1, pgs 87-93
	CAH	Beta-Lactamase Inhibitors, <i>The Pharmacological Basis of Therapeutics</i> , eighth edition, pg. 1093
	CAI	Bottenfield et al., "Safety and Tolerability of a New Formulation . . . In the Empiric Treatment of Pediatric . . . <i>Streptococcus pneumoniae</i> ", <i>Pediatric Infect. Dis. J.</i> , Vol. 17, pp. 963-968 (1998)
	CAJ	Brooks et al., "Pleuromutilins, Part 1: The Identification of Novel Mutilin 14-Carbamates", <i>Bioorganic and Medicinal Chemistry</i> 9, 2001, pgs 1221-1231

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*ATTY. DOCKET NO.
P31167C1PREDECESSOR SERIAL NO.
08/945,365APPLICANT
Bax et al.FILING DATE
HerewithPREDECESSOR GROUP
1614

B	CAK	Burgess et al., "Uptake of clavulanic acid across rat jejunal segments in vitro", J. Physiology, vol 482, pg 41
	CAL	Calver et al., "Amoxicillin/Clavulanate BID vs A/C TID in the Treatment of Lower Respiratory Tract Infections", Abstracts of the 35th ICAAC, 1995, pg 334
	CAM	Calver et al., "Augmentin Bid Versus Augmentin TID in the Treatment of Lower Respiratory Tract Infections", Can. J. Infect Dis., 1995, Vol 6 Suppl C, Abstract No. 0338, pg 239C ABSTRACT
	CAN	Calver et al., "Dosing of Amoxicillin/Clavulanate Given Every 12 Hours is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection", Clinical Infectious Disease, 1997, 24, pgs 570-574
	CAO	Catherall et al., "Distribution and Efficacy Studies with Ticarcillin-Clavulanic Acid (Timentin) in Experimental <i>Klebsiella Pneumoniae</i> Meningitis in Rabbits", Journal of Chemotherapy, 1989 supplement no 4, pgs 80-81
	CAP	Chan et al., "A comparative study of amoxicillin-clavulanate and amoxicillin. Treatment of otitis media with effusion." Archives of Otolaryngology - Head and Neck Surgery, Feb 1988, 114(2), pgs 142-146
	CAQ	Connor et al., "High Resolution 1H NMR spectroscopic Studies of the Metabolism and Excretion of ampicillin in Rats and Amoxycillin in Rats and Man", Journal of Pharm. Pharmacol. 1994, vol 46 pgs 128-134
	CAR	Cooper et al., "Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against B-lactamase-producing <i>Branhamella catarrhalis</i> and <i>Haemophilus influenzae</i> ", Journal of Antimicrobial Chemotherapy, 1990, vol. 26, pgs. 371-380
	CAS	Craig et al., "Killing and Regrowth of Bacteria in Vitro: A Review", Scand J Infect Dis., 1991, Suppl 74, pgs 63-70
	CAT	Craig et al., "Pharmacokinetics and pharmacodynamics of antibiotics in otitis media", Pediatr Infect Dis J, 1996, 15, pgs.255-259
	CAU	Craig, "Antimicrobial Resistant Issues of the Future", Diagn Microbiol Infect Dis, 1996, 25, pgs. 213-217
	CAV	Dagan et al., "Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media", Pediatric Infectious Diseases Journal, 2001, vol 20, pgs 828-837
	CAW	Dagan et al., "Bacteriological and Clinical Efficacy of a New Amoxicillin/Clavulanate formulation (A/C-ES) in the Treatment of Acute Otitis Media (AOM), ABSTRACT
	CAX	Ellis Pegler et al., "Augmentin treatment of bacterial infections in hospitalized patients", New Zealand Medical Journal, 1982, 95(713), pgs 542-545
	CAY	Everett et al., "19F NMR Spectroscopy Study of the Metabolites of Flucloxacillin in Rat Urine", Journal of Pharm. Pharmacology, 1985, vol 37, pgs 869-873
	CAZ	Everett et al., "A Study of Flucloxacillin Metabolites in Rat Urine by Two-Dimensional 1H, 19F COSY NMR", Journal of Pharmaceutical & Biomedical Analysis, 1989, vol 7, no 3, pgs 397-403
	CBA	Everett et al., "Spin echo NMR spectroscopy: A new method for studying penicillin metabolism", Chem. Commun, 1984, pgs 894-895
	CBB	Finch, "Pneumonia: The Impact of Antibiotic Resistance on its Management", Microbial Drug Resistance, Vol 1, No. 2, 1995, pgs. 149-158
	CBC	Friedland et al., "Management of infections caused by Antibiotic-Resistant <i>Streptococcus Pneumoniae</i> ", The New England Journal of Medicine, 1994, Vol. 331(6), pp 377-382
J	CBD	Hannan et al., "In Vitro Activity of Gemifloxacin (SB 265805; LB 20304a) against human mycoplasmas", The British Society for Antimicrobial Chemotherapy. 2000, vol 45, pgs 367-369

ATTY. DOCKET NO.
P31167C1PREDECESSOR SERIAL NO.
08/945,365**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Bax et al.FILING DATE
HerewithPREDECESSOR GROUP
1614

CBE	Hol et al., "Experimental Evidence for Moraxella-Induced Penicillin Neutralization in Pneumococcal Pneumonia", Journal of Infectious Disease, 1994, 170, pp 1613-1616
CBF	Ji et al., "Identification of Critical Staphylococcal Genes Using Conditional Phenotypes Generated by Antisense RNA", Science Reprint, September 21, 2001, vol 293, pgs 2266-2269
CBG	Ji et al., "Regulated Antisense RNA Eliminates Alpha-Toxin Virulence in <i>Staphylococcus aureus</i> Infection", Journal of Bacteriology, November 1999, pgs 6585-6590
CBH	Klein, "Antimicrobial Agents", Therapeutics - Part V, 1992, pgs. 2179-2198
CBI	Kucer et al., "Ampicillin-like penicillins - Amoxycillin, Epicillin, Cyclacillin, Hetacillin, Pivampicillin, Talampicillin, Bacampicillin and Metampicillin", 2) "Clavulanic Acid", The Use of Antibiotics, 1987, pgs. 172-195/271-286
CBJ	Lachman et al., "Tablet Granulations", The Theory and Practice of Industrial Pharmacy, 1986, pgs. 314-320
CBK	Legent et al., Chemotherapy (Based), "A Double-Blind Comparison of Ciprofloxacin and Amoxycillin/Clavulanic Acid in the Treatment of Chronic Sinusitis", 40(Suppl. 1), 8-15, (1994)
CBL	Lieberman et al., "Pharmaceutical Dosage Forms - Tablets Second Edition, Revised and Expanded", 1989, vol. 2, pgs. 317-334
CBM	Lister et al., "Rationale behind High-Dose Amoxicillin Therapy for Acute Otitis Media Due to Penicillin-Nonsusceptible Pnsmococci: Support from In Vitro Pharmacodynamic Studies", Antimicrobial Agents and Chemotherapy, September 1997, vol 41, no 9, pgs 1926-1932
CBN	Martindale, The Extra Pharmacopoeia, Thirtieth Edition, Edited by James E. F. Reynolds (London, The Pharmaceutical Press, 1993), pgs 115-116 and 148
CBO	McCracken, "Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics", Pediatr Infect Dis J, 1995, 14, pgs. 424-428
CBP	Merck Index 1989, 610 and 2342
CBQ	Mizen et al., "A Critique of Animal Pharmacokinetics", Journal of Antimicrobial Chemotherapy, 1988, vol 21, pgs 273-280
CBR	Mizen et al., "Simulation of Human Serum Pharmacokinetics of Ticarcillin-Clavulanic Acid and Ceftazidime in Rabbits and Efficacy Against Experimental <i>Klebsiella Pneumoniae</i> Meningitis", Antimicrobial Agents and Chemotherapy, May 1989, vol 33, no. 5, pgs 693-699
CBS	Mizen et al., "The Influence of Uptake from the Gastrointestinal Tract and First-pass Effect on Oral Bioavailability of (Z)-alkoxyimino Penicillins", Journal of Pharm. Pharmacology, 1995, vol 47, pgs 725-730
CBT	Moonsammy et al., "Improved Safety Profile of a New Amoxicillin/Clavulanate Adult BID Formulation Compared with the Standard A/C TID Formulation", Abstracts of the 36th ICAAC, 1996, pg. 290
CBU	Neu, H. C., "Other B-Lactam Antibiotics", Principles and Practice of Infectious Diseases, 1990, pgs. 257-263
CBV	Neville, "Augmentin: An in vitro study of bacterial sensitivities to a synergistic combination", New Zealand Medical Journal, 1982, 95(714), pgs 579-581
CBW	Pankuch et al., "Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin susceptible and -resistant pneumococci", Journal of Antimicrobial Chemotherapy, 1995, 35, 883-888
CBX	Pichichero, "Resistant respiratory pathogens and extended-spectrum antibiotics", American Family Physician, 1995, 52(6), pgs 1739-1746
CBY	Prescribing for Children, British National Formulary, vol. 29, pg. 11
CBZ	Repertorio Farmaceutico Italiano, 3rd Edition 1989, A106 to A108. (Translation Included)
CCA	Robinson, "Amoxicillin trihydrate/Clavulanic acid potassium salt", Med. Actual., 1982, 18(5) pgs 213-219

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*ATTY. DOCKET NO.
P31167C1PREDECESSOR SERIAL NO.
08/945,365APPLICANT
Bax et al.FILING DATE
HerewithPREDECESSOR GROUP
1614

CCB	Slocombe et al., "In Vitro and In Vivo Activity of Temocillin", Research and Clinical Forums, vol 12, no 5, pgs 21-33
CCC	Textbook of Paediatric Infectious Diseases, 3rd Edition, Volume II, Editors R. D. Feigin and J. D. Cherry, pgs. 2179-2198
CCD	Vidal 1994, 70th Edition, pgs. 132-134 (Translation Included)
CCE	Woodnutt et al, Antimicrobial Agents and Chemotherapy, "Efficacy of High-Dose Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of Streptococcus pneumonia", 43(1), 35-40, (1999)
CCF	Woodnutt et al., "Acetate entry rate into portal and peripheral blood in the rabbit", Proc. Nutr. Soc., 1979, vol 38, pg 724
CCG	Woodnutt et al., "Acetate Metabolism By Tissues of the Rabbit", Comp. Biochemical Physiol, vol 85B, no 2, pgs 487-490
CCH	Woodnutt et al., "Effect of Protein Binding on Penetration of B-Lactams into Rabbit Peripheral Lymph", Antimicrobial Agents and Chemotherapy, December 1995, vol 39, no 12, pgs 2678-2683
CCI	Woodnutt et al., "Efficite de l'association amoxicilline-acide clavulanique dans un modele d'abces sous-cutane a E. coli chez rat apres simulation de l'administration chez l'homme de lg/200mg (IVD) ou de 2g/200mg (perfusion). La lettre de l'infectiologie de la microbiologie a la clinique". Numero hors-serie. 1995, pgs 23-26
CCJ	Woodnutt et al., "Influence of Simulated Human Pharmacokinetics on the Efficacy of Temocillin Against a <i>Klebsiella Pneumoniae</i> Meningitis Infection in the Rabbit", Journal of Chemotherapy, 1989, supplement no. 4, pgs 475-476
CCK	Woodnutt et al., "Penetration of Amoxycillin, Ticarcillin and Clavulanic Acid into Lymph After Intravenous Infusion in Rabbits to Simulate Human Serum Pharmacokinetics", Journal of Antimicrobial Chemotherapy, 1990, vol 26, pgs 695-704
CCL	Woodnutt et al., "Penetration of augmentin and timentin into lymph after simulation of human serum pharmacokinetics in the rabbit", J. Drug Devel. 1989, 2, Supplement 1, pgs 123-126
CCM	Woodnutt et al., "Pharmacodynamics to Combat Resistance", Journal of Antimicrobial Chemotherapy, 2000, vol 46, Topic T1, pgs 25-31
CCN	Woodnutt et al., "Pharmacokinetics and Distribution of Ticarcillin-Clavulanic Acid (Timentin) in Experimental Animals", Antimicrobial Agents and Chemotherapy, 1987, vol 31, no 11, pgs 1826-1830
CCO	Woodnutt et al., "Rabbit liver acetyl-CoA synthetase", Biochem J., 1978, vol 175, pgs 757-759
CCP	Woodnutt et al., "Simulation of Human Serum Pharmacokinetics of Cefazolin, Piperacillin, and BRL 42715 in Rats and Efficacy Against Experimental Intraperitoneal Infections", Antimicrobial Agents and Chemotherapy, July 1992, vol 36, no. 7, pgs 1427-1431
CCQ	Woodnutt et al., "Temocillin Efficacy in Experimental <i>Klebsiella Pneumoniae</i> Meningitis after Infusion into Rabbit Plasma To Simulate Antibiotic Concentrations in Human Serum", Antimicrobial Agents and Chemotherapy, November 1988, vol 32, no 11, pgs 1705-1709
CCR	Woodnutt et al., "The Use of Two Pharmacodynamic Models for Assessing the Efficacy of Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of <i>Streptococcus pneumoniae</i> ", Antimicrobial Agents and Chemotherapy, January 1999, vol 43, no 1, pgs 29-34
CCS	The Use of Antibiotics, 4th Edition, J. B. Lippincott Company, pgs 278-279
CCT	Ball et al., "Clavulanic Acid and Amoxycillin: A Clinical, Bacteriological, and Pharmacological Study", The Lancet, March 22, 1980, Vol. I, Pgs 620-623
CCU	"Flatulence, Diarrhoea, and Polyol Sweeteners", The Lancet, December 3, 1983, Vol. II, pg 1321
CCV	Staniforth et al., "Effect of food on the bioavailability and tolerance of clavulanic acid/amoxycillin combination", Journal of Antimicrobial Chemotherapy, (1982)10, pgs 131-139
CCW	Caron et al., "Effects of Amoxicillin-Clavulanate Combination on the Motility of the Small Intestine in Human Beings", Antimicrobial Agents and Chemotherapy, June 1991, Vol. 35 No. 6, pgs 1085-1088

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31167C1	PREDECESSOR SERIAL NO. 08/945,365
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Bax et al.	
		FILING DATE Herewith	PREDECESSOR GROUP 1614

<input checked="" type="checkbox"/>	CCX	Crokaert et al., "Activities of Amoxicillin and Clavulanic Acid Combinations Against Urinary Tract Infections", Antimicrobial Agents and Chemotherapy, Aug 1982, Vol 22 No. 2, pgs 346-349
<input checked="" type="checkbox"/>	CCY	Handbook of Pharmaceutical Excipients, Third Edition, Arthur H. Kibbe, Ph.D., pgs 324-328
<input checked="" type="checkbox"/>	CCZ	Therapeutic Drugs, Dollery, 1999, pgs C253-C256
<input checked="" type="checkbox"/>	CDA	Stein et al., "Amoxicillin-potassium clavulanate, a B-lactamase-resistant antibiotic combination", Clinical Pharmacy, Vol. 3, Nov-Dec 1984 pgs 591-599
<input checked="" type="checkbox"/>	CDB	Arguedas et al., J. Antimicrob. Chemother., 27(3), pgs 311-318 ABSTRACT ONLY

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

document2